首页>
外国专利>
use of a muscarinic agent alone or together with a known anti arrhythmic drug for the prevention and / or the treatment of ventricular arrhythmias.
use of a muscarinic agent alone or together with a known anti arrhythmic drug for the prevention and / or the treatment of ventricular arrhythmias.
展开▼
机译:毒蕈碱剂单独使用或与已知的抗心律不齐药物一起用于预防和/或治疗室性心律失常的用途。
展开▼
页面导航
摘要
著录项
相似文献
摘要
The medicament contains a muscarine agonist, pref. oxotremorine, metacoline, betancol (or a salt) or pilocarpine, opt. in conjunction with an antiarrhythmic agent, pref. flecainide, encainide, quinidine, procainamide, mexiletine, lidocain, propaphenone or a slat. The muscarine agonist and the antiarrhythmic agent are pref. in separate containers. USE/ADVANTAGE - To prevent or treat malignant or acute ventricular arrhythmia (claimed). The treatment is suitable for patients at risk of sudden death, e.g. those who have suffered a myocardial infarct, or who have dilative cardiopathology or malignant ventricular arrhythmia, especially when associated with a high sympathicus tonus. In an example, arrhythmia was induced in anaesthetised cats by blocking a coronary blood vessel and electrically stimulating the left stellate ganglion. The deg. of arrhythmia was measured on a scale of 0 (no arrhythmia) to 4 (fibrillation). When the cats were given 2.5 micro-g/kg oxotremorine sesquifumarate i.v., the average score fell from 3.2 to 1.7.
展开▼